{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:29:57Z","timestamp":1792114197592,"version":"4.4.0"},"reference-count":113,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T00:00:00Z","timestamp":1607212800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Besides treating acute flares, the management of SLE should aim at preventing organ damage accrual and drug-associated harms, improving health-related quality of life and prolonging survival. At present, therapy is based on combinations of antimalarials (mainly HCQ), considered the backbone of SLE treatment, glucocorticoids and immunosuppressive drugs. However, these regimens are not universally effective and a substantial degree of damage can be caused by exposure to glucocorticoids. In this review we provide a critical appraisal of the efficacy and safety of available treatments as well as a brief discussion of potentially novel compounds in patients with SLE. We emphasize the use of methylprednisolone pulses for moderate\u2013severe flares, followed by low\u2013moderate doses of oral prednisone with quick tapering to maintenance doses of \u22645\u2009mg\/day, as well as the prompt institution of immunosuppressive drugs in the setting of severe disease but also as steroid-sparing agents. Indications for the use of biologic agents, namely belimumab and rituximab, in refractory or organ-threatening disease are also presented. We conclude by proposing evidence- and experience-based treatment strategies tailored to the clinical scenario and prevailing organ involvement that can aid clinicians in managing this complex disease.<\/jats:p>","DOI":"10.1093\/rheumatology\/keaa403","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T19:12:48Z","timestamp":1592593968000},"page":"v69-v81","source":"Crossref","is-referenced-by-count":136,"title":["Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-1043","authenticated-orcid":false,"given":"Guillermo","family":"Ruiz-Irastorza","sequence":"first","affiliation":[{"name":"Autoimmune Diseases Research Unit, Internal Medicine Department, Biocruces Bizkaia Health Research Institute, University of the Basque Country, Barakaldo, Bizkaia, Bilbao, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bertsias","sequence":"additional","affiliation":[{"name":"Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School and University Hospital of Iraklio, Iraklio, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"2020120517370179300_keaa403-B1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0961203307086643","article-title":"Hydroxychloroquine: the cornerstone of lupus therapy","volume":"17","author":"Ruiz-Irastorza","year":"2008","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"2020120517370179300_keaa403-B3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2007.070367","article-title":"EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics","volume":"67","author":"Bertsias","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B5","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort","volume":"66","author":"Alarc\u00f3n","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B6","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/art.27300","article-title":"Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort","volume":"62","author":"Shinjo","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2020120517370179300_keaa403-B7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0961203317739129","article-title":"Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort","volume":"27","author":"Mok","year":"2018","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3899\/jrheum.170645","article-title":"More consistent antimalarial intake in first 5 years of disease is associated with better prognosis in patients with systemic lupus erythematosus","volume":"45","author":"Pakchotanon","year":"2018","journal-title":"J Rheumatol"},{"key":"2020120517370179300_keaa403-B10","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2764","article-title":"Predictors of major infections in systemic lupus erythematosus","volume":"11","author":"Ruiz-Irastorza","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2020120517370179300_keaa403-B11","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1177\/0961203318811598","article-title":"Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort","volume":"27","author":"Gonzalez-Echavarri","year":"2018","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/0961203319860579","article-title":"Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort","volume":"28","author":"Pimentel-Quiroz","year":"2019","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.semarthrit.2017.01.010","article-title":"Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus","volume":"47","author":"R\u00faa-Figueroa","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2020120517370179300_keaa403-B14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/ard.2006.067777","article-title":"Antimalarials may influence the risk of malignancy in systemic lupus erythematosus","volume":"66","author":"Ruiz-Irastorza","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/CLEP.S143563","article-title":"Effects of chronic exposure of hydroxychloroquine\/chloroquine on the risk of cancer, metastasis, and death: a population-based cohort study on patients with connective tissue diseases","volume":"9","author":"Fardet","year":"2017","journal-title":"Clin Epidemiol"},{"key":"2020120517370179300_keaa403-B16","first-page":"620","article-title":"Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14832 patients with systemic lupus erythematosus: a nested case\u2013control study","volume":"56","author":"Hsu","year":"2017","journal-title":"Rheumatology"},{"key":"2020120517370179300_keaa403-B17","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B18","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology"},{"key":"2020120517370179300_keaa403-B19","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2020120517370179300_keaa403-B21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1177\/0961203317734922","article-title":"Antimalarial-induced cardiomyopathy: a systematic review of the literature","volume":"27","author":"Tselios","year":"2018","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B23","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","author":"Mehra","year":"2020","journal-title":"Lancet"},{"key":"2020120517370179300_keaa403-B24","first-page":"545","article-title":"Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus","volume":"36","author":"McGhie","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2020120517370179300_keaa403-B25","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"2020120517370179300_keaa403-B26","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","article-title":"The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy","volume":"132","author":"Melles","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2020120517370179300_keaa403-B27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0961203319829826","article-title":"Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus","volume":"28","author":"Mart\u00edn-Iglesias","year":"2019","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B28","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1002\/art.22156","article-title":"Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus","volume":"54","author":"Costedoat-Chalumeau","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020120517370179300_keaa403-B29","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","article-title":"Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)","volume":"72","author":"Costedoat-Chalumeau","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/cpt.1194","article-title":"A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires","volume":"106","author":"Costedoat-Chalumeau","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2020120517370179300_keaa403-B31","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1177\/0961203318768877","article-title":"Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity","volume":"27","author":"Ugarte","year":"2018","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B32","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/BOR.0000000000000527","article-title":"Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions","volume":"30","author":"Ugarte","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2020120517370179300_keaa403-B33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and nongenomic effects of glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2020120517370179300_keaa403-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12364","article-title":"Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity","volume":"1318","author":"Strehl","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"2020120517370179300_keaa403-B35","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1002\/art.20583","article-title":"Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action","volume":"50","author":"Buttgereit","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2020120517370179300_keaa403-B36","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B37","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/rheumatology\/keu148","article-title":"Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus","volume":"53","author":"Ruiz-Arruza","year":"2014","journal-title":"Rheumatology"},{"key":"2020120517370179300_keaa403-B38","doi-asserted-by":"crossref","first-page":"e000157","DOI":"10.1136\/lupus-2016-000157","article-title":"Independent association of glucocorticoids with damage accrual in SLE","volume":"3","author":"Apostolopoulos","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2020120517370179300_keaa403-B39","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2020120517370179300_keaa403-B40","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B41","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3899\/jrheum.120537","article-title":"Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study","volume":"39","author":"Fischer-Betz","year":"2012","journal-title":"J Rheumatol"},{"key":"2020120517370179300_keaa403-B42","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.autrev.2013.10.013","article-title":"Prednisone in lupus nephritis: how much is enough?","volume":"13","author":"Ruiz-Irastorza","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2020120517370179300_keaa403-B44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.autrev.2017.05.017","article-title":"Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts","volume":"16","author":"Ruiz-Irastorza","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2020120517370179300_keaa403-B45","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"key":"2020120517370179300_keaa403-B46","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2015.05.011","article-title":"Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis","volume":"14","author":"Ruiz-Arruza","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2020120517370179300_keaa403-B47","doi-asserted-by":"crossref","first-page":"e000153","DOI":"10.1136\/lupus-2016-000153","article-title":"First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort","volume":"3","author":"Ruiz-Irastorza","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2020120517370179300_keaa403-B48","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/acr.23322","article-title":"Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study","volume":"70","author":"Ruiz-Arruza","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2020120517370179300_keaa403-B49","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.autrev.2019.102359","article-title":"Prolonged remission in SLE is possible by using reduced doses of prednisone: an observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts","volume":"18","author":"Ruiz-Irastorza","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2020120517370179300_keaa403-B50","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.24068","article-title":"Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"59","author":"Fortin","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020120517370179300_keaa403-B51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0961203313519159","article-title":"Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy","volume":"23","author":"Sakthiswary","year":"2014","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B52","doi-asserted-by":"crossref","first-page":"e000105","DOI":"10.1136\/lupus-2015-000105","article-title":"Characteristics of azathioprine use and cessation in a longitudinal lupus cohort","volume":"2","author":"Croyle","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2020120517370179300_keaa403-B53","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/rheumatology\/kep396","article-title":"The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE","volume":"49","author":"Griffiths","year":"2010","journal-title":"Rheumatology (Oxford"},{"key":"2020120517370179300_keaa403-B54","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","article-title":"Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial","volume":"76","author":"Ordi-Ros","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B55","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3899\/jrheum.150779","article-title":"Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study","volume":"43","author":"Tselios","year":"2016","journal-title":"J Rheumatol"},{"key":"2020120517370179300_keaa403-B56","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.40057","article-title":"Effect of corticosteroids and cyclophosphamide on sex hormone profiles in male patients with systemic lupus erythematosus or systemic sclerosis","volume":"69","author":"Arnaud","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370179300_keaa403-B57","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3899\/jrheum.180310","article-title":"Zoster after cyclophosphamide for systemic lupus erythematosus or vasculitis: incidence, risk factors, and effect of antiviral prophylaxis","volume":"45","author":"Garnier","year":"2018","journal-title":"J Rheumatol"},{"key":"2020120517370179300_keaa403-B58","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/ard.2010.130476","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs","volume":"69","author":"Bertsias","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B59","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/0961203315622821","article-title":"Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study","volume":"25","author":"Fanouriakis","year":"2016","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B60","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.berh.2017.09.010","article-title":"inhibitors in systemic lupus erythematosus","volume":"31","author":"Mok","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2020120517370179300_keaa403-B61","doi-asserted-by":"crossref","first-page":"e000274","DOI":"10.1136\/lupus-2018-000274","article-title":"Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres","volume":"5","author":"Tani","year":"2018","journal-title":"Lupus Sci Med"},{"key":"2020120517370179300_keaa403-B62","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"key":"2020120517370179300_keaa403-B63","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/art.40079","article-title":"Brief report: the Euro-Lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of anti-M\u00fcllerian hormone","volume":"69","author":"Tamirou","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370179300_keaa403-B64","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2020120517370179300_keaa403-B65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020120517370179300_keaa403-B66","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3899\/jrheum.130005","article-title":"Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment","volume":"41","author":"Touma","year":"2014","journal-title":"J Rheumatol"},{"key":"2020120517370179300_keaa403-B67","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1681\/ASN.2017030263","article-title":"Multitarget therapy for maintenance treatment of lupus nephritis","volume":"28","author":"Zhang","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2020120517370179300_keaa403-B68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B69","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/rheumatology\/keu265","article-title":"Long-term data on tacrolimus treatment in lupus nephritis","volume":"53","author":"Yap","year":"2014","journal-title":"Rheumatology (Oxford"},{"key":"2020120517370179300_keaa403-B70","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B71","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370179300_keaa403-B72","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B73","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/annrheumdis-2018-214427","article-title":"Lupus low disease activity state (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus","volume":"78","author":"Oon","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B74","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/art.39682","article-title":"Cumulative corticosteroid dose over fifty-two weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials","volume":"68","author":"van Vollenhoven","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370179300_keaa403-B75","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/0961203315625119","article-title":"Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care","volume":"25","author":"Bruce","year":"2016","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B76","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/annrheumdis-2018-214043","article-title":"Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis","volume":"78","author":"Urowitz","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B77","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/acr.23788","article-title":"Long-term impact of belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: six years of treatment","volume":"71","author":"Strand","year":"2019","journal-title":"Arthritis Care Res (Hoboken"},{"key":"2020120517370179300_keaa403-B78","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B79","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/art.40439","article-title":"Long-term safety and efficacy of belimumab in patients with systemic lupus erythematosus: a continuation of a seventy-six-week phase III parent study in the United States","volume":"70","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370179300_keaa403-B80","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/rheumatology\/kez279","article-title":"Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a phase III study extension","volume":"59","author":"van Vollenhoven","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2020120517370179300_keaa403-B81","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/art.40511","article-title":"Efficacy and safety of subcutaneous belimumab in anti-double-stranded DNA-positive, hypocomplementemic patients with systemic lupus erythematosus","volume":"70","author":"Doria","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370179300_keaa403-B82","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1136\/annrheumdis-2011-200937","article-title":"Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response","volume":"71","author":"van Vollenhoven","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B83","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/03009742.2019.1603324","article-title":"Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting","volume":"48","author":"Anjo","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"2020120517370179300_keaa403-B84","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.semarthrit.2018.02.014","article-title":"Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: a real-life observational study","volume":"48","author":"Fanouriakis","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2020120517370179300_keaa403-B85","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/14712598.2018.1494719","article-title":"Smoking reduces the efficacy of belimumab in mucocutaneous lupus","volume":"18","author":"Parodis","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"2020120517370179300_keaa403-B86","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kez191","article-title":"Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus","volume":"58","author":"Parodis","year":"2019","journal-title":"Rheumatology (Oxford"},{"key":"2020120517370179300_keaa403-B87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.09.004","article-title":"Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study","volume":"86","author":"Iaccarino","year":"2018","journal-title":"J Autoimmun"},{"key":"2020120517370179300_keaa403-B88","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.40861","article-title":"Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370179300_keaa403-B89","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.4049\/jimmunol.1600281","article-title":"BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis","volume":"198","author":"Kang","year":"2017","journal-title":"J Immunol"},{"key":"2020120517370179300_keaa403-B90","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B91","article-title":"GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis"},{"key":"2020120517370179300_keaa403-B92","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2020120517370179300_keaa403-B93","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2020120517370179300_keaa403-B94","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/annrheumdis-2018-214833","article-title":"Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study","volume":"78","author":"Scherlinger","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B95","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review","volume":"44","author":"Cobo-Ibanez","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2020120517370179300_keaa403-B96","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/rheumatology\/kex395","article-title":"Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the","volume":"57","author":"McCarthy","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2020120517370179300_keaa403-B97","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B98","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jamadermatol.2018.3793","article-title":"Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus","volume":"154","author":"Quelhas da Costa","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2020120517370179300_keaa403-B99","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am J Hematol"},{"key":"2020120517370179300_keaa403-B100","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40932","article-title":"Rituximab as maintenance treatment for systemic lupus erythematosus: a multicenter observational study of 147 patients","volume":"71","author":"Cassia","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2020120517370179300_keaa403-B101","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology (Oxford"},{"key":"2020120517370179300_keaa403-B102","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"2020120517370179300_keaa403-B103","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/exd.13253","article-title":"JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus","volume":"26","author":"Klaeschen","year":"2017","journal-title":"Exp Dermatol"},{"key":"2020120517370179300_keaa403-B104","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/annrheumdis-2019-216571","article-title":"Efficacy of JAK 1\/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus","volume":"79","author":"Maeshima","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"2020120517370179300_keaa403-B106","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B107","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2020120517370179300_keaa403-B108","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaa060","article-title":"Inhibition of mTOR suppresses IFN\u03b1 production and the STING pathway in monocytes from systemic lupus erythematosus patients","volume":"59","author":"Murayama","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2020120517370179300_keaa403-B109","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/rheumatology\/kex444","article-title":"Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort","volume":"57","author":"Little","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2020120517370179300_keaa403-B110","doi-asserted-by":"crossref","first-page":"e000310","DOI":"10.1136\/lupus-2018-000310","article-title":"Changing paradigms in the treatment of systemic lupus erythematosus","volume":"6","author":"Fanouriakis","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2020120517370179300_keaa403-B111","doi-asserted-by":"crossref","DOI":"10.1177\/0961203320930099","article-title":"Seventy years after Hench\u2019s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus","author":"Ruiz-Irastorza","year":"2020","journal-title":"Lupus"},{"key":"2020120517370179300_keaa403-B112","author":"Ruiz-Irastorza"},{"key":"2020120517370179300_keaa403-B113","first-page":"643","article-title":"Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series","volume":"36","author":"Gualtierotti","year":"2018","journal-title":"Clin Exp Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/Supplement_5\/v69\/34729967\/keaa403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/Supplement_5\/v69\/34729967\/keaa403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T22:37:27Z","timestamp":1607207847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/Supplement_5\/v69\/6024729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":113,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2020,12,5]]},"published-print":{"date-parts":[[2020,12,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa403","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,12]]}}}